Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Taming the sinister side of BMT: Dr. Jekyll and Mr. Hyde

Suicidal donor T lymphocytes halt GvHD thereby favoring the graft-versus-tumor effect in allogeneic BMT patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

References

  1. Thomas, E.D. et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann. Intern. Med. 104, 155–163 (1986).

    Article  CAS  Google Scholar 

  2. Bonini, C. et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 276, 1719–1724 (1997).

    Article  CAS  Google Scholar 

  3. Wallny, H.-J. & Rammense, H.-G. Identification of classical minor histocompatibility antigen as cell-derived peptide. Nature. 343, 275–284 (1990).

    Article  CAS  Google Scholar 

  4. Vogelsang, G.B. & Hess, A.D. Graft-versus-host disease: New directions for a persistent problem. Blood 84, 2061–2062 (1994).

    CAS  PubMed  Google Scholar 

  5. Den Haan, J.M. Identification of graft-versus-host disease associated human minor histocompatibility antigen. Science 268, 1476–1480 (1995).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pardoll, D. Taming the sinister side of BMT: Dr. Jekyll and Mr. Hyde. Nat Med 3, 833–834 (1997). https://doi.org/10.1038/nm0897-833

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0897-833

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing